25-Hydroxycholesterol and inflammation in Lovastatin-deregulated mevalonate pathway

Paola Maura Tricarico, Rossella Gratton, Luca Braga, Fulvio Celsi, Sergio Crovella

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Mevalonate pathway deregulation has been observed in several diseases, including Mevalonate kinase deficiency (MKD). MKD is a hereditary auto-inflammatory disorder, due to mutations at mevalonate kinase gene (MVK), encoding mevalonate kinase (MK) enzyme. MVK mutations have been reported as associated with impairment of mevalonate pathway with consequent decrease of protein prenylation levels, defective autophagy and increase of IL-1β secretion, followed by cell death. Since 25-hydroxycholesterol (25-HC), a metabolite of cholesterol, can suppress IL-1β production, thus reducing inflammation, we evaluated the effect of 25-HC in an in vitro model of mevalonate pathway alteration, obtained using Lovastatin. Human glioblastoma cell line (U87-MG) was chosen to mimic, at least in part, the central nervous system impairment observed in MKD; 25-HC effects were evaluated aimed at disclosing if this compound could be considered as novel potential drug for MKD. Our results showed that 25-HC is able to reduce inflammation but it is ineffective to restore autophagy flux and to decrease apoptosis levels, both caused by lower protein prenylation; so, in spite of its anti-inflammatory action it is not useful to rescue defective prenylation/autophagy impairment-driven apoptosis in Lovastatin impaired mevalonate pathway. We hypothesize the presence in the mevalonate pathway of alternative mechanisms acting between inflammation and apoptotic autophagy impairment.

Original languageEnglish
Pages (from-to)26-33
Number of pages8
JournalInternational Journal of Biochemistry and Cell Biology
Volume92
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

mevalonate kinase
Mevalonate Kinase Deficiency
Lovastatin
Mevalonic Acid
Autophagy
Inflammation
Protein Prenylation
Interleukin-1
Apoptosis
Prenylation
Mutation
Glioblastoma
Genes
Gene encoding
Deregulation
Cell Death
Anti-Inflammatory Agents
Central Nervous System
Neurology
Cell death

Keywords

  • 25-Hydroxycholesterol
  • Apoptosis
  • Autophagy flux
  • Inflammation
  • Mevalonate kinase deficiency
  • Prenylation levels

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

@article{0bbca5a56556427f96e7007519c52dab,
title = "25-Hydroxycholesterol and inflammation in Lovastatin-deregulated mevalonate pathway",
abstract = "Mevalonate pathway deregulation has been observed in several diseases, including Mevalonate kinase deficiency (MKD). MKD is a hereditary auto-inflammatory disorder, due to mutations at mevalonate kinase gene (MVK), encoding mevalonate kinase (MK) enzyme. MVK mutations have been reported as associated with impairment of mevalonate pathway with consequent decrease of protein prenylation levels, defective autophagy and increase of IL-1β secretion, followed by cell death. Since 25-hydroxycholesterol (25-HC), a metabolite of cholesterol, can suppress IL-1β production, thus reducing inflammation, we evaluated the effect of 25-HC in an in vitro model of mevalonate pathway alteration, obtained using Lovastatin. Human glioblastoma cell line (U87-MG) was chosen to mimic, at least in part, the central nervous system impairment observed in MKD; 25-HC effects were evaluated aimed at disclosing if this compound could be considered as novel potential drug for MKD. Our results showed that 25-HC is able to reduce inflammation but it is ineffective to restore autophagy flux and to decrease apoptosis levels, both caused by lower protein prenylation; so, in spite of its anti-inflammatory action it is not useful to rescue defective prenylation/autophagy impairment-driven apoptosis in Lovastatin impaired mevalonate pathway. We hypothesize the presence in the mevalonate pathway of alternative mechanisms acting between inflammation and apoptotic autophagy impairment.",
keywords = "25-Hydroxycholesterol, Apoptosis, Autophagy flux, Inflammation, Mevalonate kinase deficiency, Prenylation levels",
author = "Tricarico, {Paola Maura} and Rossella Gratton and Luca Braga and Fulvio Celsi and Sergio Crovella",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.biocel.2017.09.007",
language = "English",
volume = "92",
pages = "26--33",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - 25-Hydroxycholesterol and inflammation in Lovastatin-deregulated mevalonate pathway

AU - Tricarico, Paola Maura

AU - Gratton, Rossella

AU - Braga, Luca

AU - Celsi, Fulvio

AU - Crovella, Sergio

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Mevalonate pathway deregulation has been observed in several diseases, including Mevalonate kinase deficiency (MKD). MKD is a hereditary auto-inflammatory disorder, due to mutations at mevalonate kinase gene (MVK), encoding mevalonate kinase (MK) enzyme. MVK mutations have been reported as associated with impairment of mevalonate pathway with consequent decrease of protein prenylation levels, defective autophagy and increase of IL-1β secretion, followed by cell death. Since 25-hydroxycholesterol (25-HC), a metabolite of cholesterol, can suppress IL-1β production, thus reducing inflammation, we evaluated the effect of 25-HC in an in vitro model of mevalonate pathway alteration, obtained using Lovastatin. Human glioblastoma cell line (U87-MG) was chosen to mimic, at least in part, the central nervous system impairment observed in MKD; 25-HC effects were evaluated aimed at disclosing if this compound could be considered as novel potential drug for MKD. Our results showed that 25-HC is able to reduce inflammation but it is ineffective to restore autophagy flux and to decrease apoptosis levels, both caused by lower protein prenylation; so, in spite of its anti-inflammatory action it is not useful to rescue defective prenylation/autophagy impairment-driven apoptosis in Lovastatin impaired mevalonate pathway. We hypothesize the presence in the mevalonate pathway of alternative mechanisms acting between inflammation and apoptotic autophagy impairment.

AB - Mevalonate pathway deregulation has been observed in several diseases, including Mevalonate kinase deficiency (MKD). MKD is a hereditary auto-inflammatory disorder, due to mutations at mevalonate kinase gene (MVK), encoding mevalonate kinase (MK) enzyme. MVK mutations have been reported as associated with impairment of mevalonate pathway with consequent decrease of protein prenylation levels, defective autophagy and increase of IL-1β secretion, followed by cell death. Since 25-hydroxycholesterol (25-HC), a metabolite of cholesterol, can suppress IL-1β production, thus reducing inflammation, we evaluated the effect of 25-HC in an in vitro model of mevalonate pathway alteration, obtained using Lovastatin. Human glioblastoma cell line (U87-MG) was chosen to mimic, at least in part, the central nervous system impairment observed in MKD; 25-HC effects were evaluated aimed at disclosing if this compound could be considered as novel potential drug for MKD. Our results showed that 25-HC is able to reduce inflammation but it is ineffective to restore autophagy flux and to decrease apoptosis levels, both caused by lower protein prenylation; so, in spite of its anti-inflammatory action it is not useful to rescue defective prenylation/autophagy impairment-driven apoptosis in Lovastatin impaired mevalonate pathway. We hypothesize the presence in the mevalonate pathway of alternative mechanisms acting between inflammation and apoptotic autophagy impairment.

KW - 25-Hydroxycholesterol

KW - Apoptosis

KW - Autophagy flux

KW - Inflammation

KW - Mevalonate kinase deficiency

KW - Prenylation levels

UR - http://www.scopus.com/inward/record.url?scp=85029477410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029477410&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2017.09.007

DO - 10.1016/j.biocel.2017.09.007

M3 - Article

C2 - 28918367

AN - SCOPUS:85029477410

VL - 92

SP - 26

EP - 33

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

ER -